Compositions and methods to prevent cancer with cupredoxins

Abstract

The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa , and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.

1. An isolated peptide, wherein the peptide consists of residues 50-77 of SEQ ID NO: 1 and can inhibit the development of premalignant lesions in mammalian tissue. 
     
     
       2. A pharmaceutical composition, comprising the peptide of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       3. The pharmaceutical composition of  claim 2 , wherein the pharmaceutically acceptable carrier is suitable for intravenous administration. 
     
     
       4. A kit comprising the pharmaceutical composition of  claim 3  in a vial. 
     
     
       5. A method to treat a mammalian patient having premalignant lesions, comprising administering to the patient a therapeutically effective amount of the composition of  claim 2 , wherein the development of premalignant lesions is inhibited. 
     
     
       6. The method of  claim 5 , wherein the patient is human. 
     
     
       7. The method of  claim 5 , wherein the patient is at a higher risk to develop cancer than the general population. 
     
     
       8. The method of  claim 7 , wherein the cancer is selected from melanoma, breast, pancreas, glioblastoma, astrocytoma, lung, colorectal, neck and head, bladder, prostate, skin, and cervical cancer. 
     
     
       9. The method of  claim 7 , wherein the patient has at least one high risk feature. 
     
     
       10. The method of  claim 7 , wherein the pharmaceutical composition is co-administered with at least one other chemopreventive drug. 
     
     
       11. The method of  claim 10 , wherein the pharmaceutical composition is administered at about the same time as another chemopreventive drug. 
     
     
       12. The method of  claim 5 , wherein the pharmaceutical composition is administered by a mode selected from the group consisting of intravenous injection, intramuscular injection, subcutaneous injection, inhalation, topical administration, transdermal patch, suppository, vitreous injection and oral. 
     
     
       13. The method of  claim 12 , wherein the mode of administration is by intravenous injection.